CIRC (01763) announced that its subsidiary, Atom High-Tech Co., Ltd., has officially signed a commercial cooperation agreement with Novartis Pharma Tech (Zhejiang) Co., Ltd. (Novartis AG) for Pluvicto® (lutetium [177Lu] vipivotide tetraxetan injection).

Pluvicto® is the first and currently the only approved PSMA-targeted radioligand therapy in China, primarily used for treating advanced prostate cancer. It offers a novel nuclear medicine treatment option aimed at prolonging patients' lives and improving their quality of life.

This agreement marks the beginning of a strategic collaboration between the two companies in the innovative nuclear medicine product Pluvicto®. Leveraging its years of compliant operational experience in the radiopharmaceutical sector, Atom High-Tech will join forces with Novartis AG to provide customized Pluvicto® product supply and solutions for medical institutions and patients, benefiting a broader patient population.